Biobank For MS And Other Demyelinating Diseases

StatusActive, Not Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion date: Oct 2026 to Oct 2030v20
  2. Study Status, Referencesv19
  3. Minor Study completion date: Oct 2036v18
  4. 2 versions Re-verified since Jan 13, 2018, no change to tracked fieldsv16-v17
  5. Minor Enrollment target: 3226
    • Primary completion date: Oct 2026
    v15
Show 13 earlier versionsHide 13 earlier versions
  1. Minor Trial status: Enrolling by Invitation to Active, Not Recruitingv14
  2. Minor Trial status: Recruiting to Enrolling by Invitation
    • Site details revised at 10 of 10 sites
    v13
  3. Minor Site contacts updated at 10 of 10 sitesv12
  4. Minor Study sites: 9 to 10v11
  5. Minor Study sites: 8 to 9v10
  6. Minor Study sites: 6 to 8v9
  7. Re-verified, no change to tracked fieldsv8
  8. Minor Eligibility criteria expanded, about 27 wordsv7
  9. Minor Site contacts updated at 6 of 6 sitesv6
  10. Minor Site contacts updated at 1 of 6 sitesv5
  11. Minor Site details revised at 1 of 6 sitesv4
  12. Minor Site contacts updated at 1 of 6 sitesv3
  13. Minor Site contacts updated at 2 of 6 sitesv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To establish a large, longitudinal collection of high quality samples and data from subjects with MS, selected other demyelinating diseases (Transverse Myelitis (TM), Neuromyelitis Optica (NMO) or Devic's, Acute Disseminated Encephalomyelitis (ADEM), and Optic Neuritis (ON)), and related and unrelated unaffected controls. Samples and data will be available as a shared resource to scientists researching the causes, sub-types, and biomarkers of MS and related demyelinating diseases.
Trial Details
NCT Number NCT00445367
Lead Sponsor Accelerated Cure Project for Multiple Sclerosis
Conditions
(from sponsor)
Multiple Sclerosis, Transverse Myelitis, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, Optic Neuritis
Related terms Encephalomyelitis, Acute Disseminated, Multiple Sclerosis, Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis
Enrollment 3,226 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov